作者: Natalie J. Galant , Per Westermark , Jeffrey N. Higaki , Avijit Chakrabartty
DOI: 10.1042/CS20160413
关键词: Cardiomyopathy 、 Intensive care medicine 、 Attr amyloidosis 、 Cardiac amyloidosis 、 Transthyretin 、 Heart disease 、 Heart failure 、 Pathology 、 Medicine 、 Amyloidosis 、 Polyneuropathy
摘要: Transthyretin (TTR) amyloidosis (ATTR amyloidosis) is an underdiagnosed and important type of cardiomyopathy and/or polyneuropathy that requires increased awareness within the medical community. Raising among clinicians about this neuropathy lethal form of heart disease critical for improving earlier diagnosis identification patients treatment. The following review summarizes current criteria used to diagnose both hereditary wild-type ATTR (ATTRwt) amyloidosis, tools available improve diagnostic accuracy, newly developing therapeutics, as well a brief biochemical biophysical background TTR amyloidogenesis.